Abstract
Sean A. Fletcher, Nicholas A. Pickersgill, Nate Aiken, Melissa J. Assel, Nicole Liso, Victor E. Reuter, Behfar Ehdaie, Samson W. Fine, Andrew J. Vickers
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Time trends and variation in the use of active surveillance for management of low‐risk prostate cancer in the US
10.1001/jamanetworkopen.2023.1439 · 2023
Long‐term follow‐up of a large active surveillance cohort of patients with prostate cancer
10.1200/jco.2014.55.1192 · 2015
Fifteen‐year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
10.1056/nejmoa2214122 · 2023
Rethinking Gleason pattern quantification in predicting metastasis: results of 20 years of follow‐up in the Rotterdam section of the European randomized study of screening for prostate cancer
10.1111/his.70052 · 2026
Disease‐specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy
10.1111/bju.12879 · 2015
Risk of biochemical recurrence in patients with grade group 1 prostate cancer with extraprostatic extension treated with radical prostatectomy
10.1097/ju.0000000000003825 · 2024
Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology
10.6004/jnccn.2023.0050 · 2023
A new risk classification system for therapeutic decision making with intermediate‐risk prostate cancer patients undergoing dose‐escalated external‐beam radiation therapy
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.eururo.2013.03.033 · 2013
Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk‐based management. [Miscellaneous Article]
10.1097/ju.0000000000002757 · 2022
EAU‐EANM‐ESTRO‐ESUR‐ISUP‐SIOG guidelines on prostate cancer—2024 update. Part I: screening, diagnosis, and local treatment with curative intent
10.1016/j.eururo.2024.03.027 · 2024
The absolute volume of Gleason pattern 4 on radical prostatectomy is more strongly associated with advanced stage and biochemical recurrence than Gleason grade groups
10.1097/ju.0000000000004484 · 2025
10.64898/2026.02.27.26347289
10.64898/2026.02.27.26347289
Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome
10.1111/bju.16884 · 2025
Oncologic outcomes of total length Gleason pattern 4 on biopsy in men with grade group 2 prostate cancer
10.1097/ju.0000000000002685 · 2022
Unresolved referenced work
2021
Welcome to the tidyverse
10.21105/joss.01686 · 2019
Reproducible summary tables with the gtsummary package
10.32614/rj-2021-053 · 2021
Clinical usefulness of total length of Gleason pattern 4 on biopsy in men with grade group 2 prostate cancer
10.1016/j.juro.2018.07.062 · 2019
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
10.1001/jama.280.11.969 · 1998
The use and short‐term outcomes of active surveillance in men with National Comprehensive Cancer Network favorable intermediate‐risk prostate cancer: the initial Michigan urological surgery improvement collaborative experience
10.1097/ju.0000000000003012 · 2023
Revisiting prostate cancer active surveillance candidacy
10.1016/s1470-2045(25)00438-3 · 2025
Identifying men who can remain on active surveillance despite biopsy reclassification to grade group 2 prostate cancer
10.1097/ju.0000000000003461 · 2023
Quantification of Gleason pattern 4 metrics identifies pathologic progression in patients with grade group 2 prostate cancer on active surveillance
10.1016/j.clgc.2024.102204 · 2024
Cancer statistics, 2026
2026
Unresolved referenced work
2026
Prostate cancer grade migration and facility‐level treatment trends for grade group 1 disease
10.1093/jncics/pkad018 · 2023
Differences in survival of prostate cancer Gleason 8–10 disease and the establishment of a new Gleason survival grading system
10.1002/cam4.3571 · 2020
Cost‐effectiveness and evidence gaps surrounding PSMA‐PET for recurrent prostate cancer evaluation
10.1001/jamanetworkopen.2025.39250 · 2025
Adverse effects of androgen deprivation therapy and strategies to mitigate them
10.1016/j.eururo.2014.07.010 · 2015
Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings
10.1097/pas.0b013e3182217b79 · 2011
Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue
10.1111/j.1365-2559.2008.03087.x · 2008
Evaluating tumor quantification in place of proportions in prostate cancer: principles of the ProQuant group
10.1016/j.eururo.2025.11.013 · 2026
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage
10.1111/his.15231 · 2024
Long‐term outcomes of cribriform‐positive and cribriform‐negative prostate cancer treated with radical prostatectomy in the ProtecT trial
10.1111/bju.70261 · 2026
No additional external references are available.